1 The eects of several phosphodiesterase (PDE) inhibitors on the L-type Ca current (I Ca ) and intracellular cyclic AMP concentration ([cAMP] i ) were examined in isolated rat ventricular myocytes. The presence of mRNA transcripts encoding for the dierent cardiac PDE subtypes was con®rmed by RT ± PCR. 2 IBMX (100 mM), a broad-spectrum PDE inhibitor, increased basal I Ca by 120% and [cAMP] i by 70%, similarly to a saturating concentration of the b-adrenoceptor agonist isoprenaline (1 mM). However, MIMX (1 mM), a PDE1 inhibitor, EHNA (10 mM), a PDE2 inhibitor, cilostamide (0.1 mM), a PDE3 inhibitor, or Ro 20-1724 (0.1 mM), a PDE4 inhibitor, had no eect on basal I Ca and little stimulatory eects on [cAMP] i (20 ± 30%). 3 Each selective PDE inhibitor was then tested in the presence of another inhibitor to examine whether a concomitant inhibition of two PDE subtypes had any eect on I Ca or [cAMP] i . While all combinations tested signi®cantly increased [cAMP] i (40 ± 50%), only cilostamide (0.1 mM)+Ro20-1724 (0.1 mM) produced a signi®cant stimulation of I Ca (50%). Addition of EHNA (10 mM) to this mix increased I Ca to 110% and [cAMP] i to 70% above basal, i.e. to similar levels as obtained with IBMX (100 mM) or isoprenaline (1 mM). 4 When tested on top of a sub-maximal concentration of isoprenaline (1 nM), which increased I Ca by (&40% and had negligible eect on [cAMP] i , each selective PDE inhibitor induced a clear stimulation of [cAMP] i and an additional increase in I Ca . Maximal eects on I Ca were &8% for MIMX (3 mM), &20% for EHNA (1 ± 3 mM), &30% for cilostamide (0.3 ± 1 mM) and &50% for Ro20-1724 (0.1 mM). 5 Our results demonstrate that PDE1-4 subtypes regulate I Ca in rat ventricular myocytes. While PDE3 and PDE4 are the dominant PDE subtypes involved in the regulation of basal I Ca , all four PDE subtypes determine the response of I Ca to a stimulus activating cyclic AMP production, with the rank order of potency PDE44PDE34PDE24PDE1.
Introduction
Phosphorylation of cardiac L-type Ca 2+ channels by cyclic AMP-dependent protein kinase (PKA) plays a determinant role in the hormonal regulation of myocardial contraction. PKA increases the mean open probability of individual Ca 2+ channels which results in an increase in the macroscopic L-type calcium current (I Ca ) (McDonald et al., 1994) . Activation of PKA usually results from an increased production of cyclic AMP by activation of membrane receptors positively coupled to adenylyl cyclase via stimulatory G proteins (G s ). The best documented of such a regulation is the positive inotropic eect of sympathomimetic amines, such as isoprenaline Hove-Madsen et al., 1996) . However, cardiac myocytes, as most other cell types, also possess a negative feedback mechanism to adenylyl cyclase activation which is constituted of the cyclic nucleotide phosphodiesterases (PDEs), a family of enzymes that break down cyclic AMP into 5'-AMP (Beavo, 1995) . Cyclic nucleotide PDE activity, at any given location within the cell, will counterbalance the synthesis of cyclic AMP and determine the extent of PKA activation and, hence, of protein phosphorylation. In particular, at the sarcolemmal membrane, this balance between adenylyl cyclase and PDE activities will control the degree of I Ca stimulation upon hormonal activation Hove-Madsen et al., 1996) . Other factors are involved, such as cyclic AMP compartmentation , PKA tethering to the membrane (Gao et al., 1997) , or phosphatase activity (Wiechen et al., 1995) .
Cyclic nucleotide PDEs exist in multiple molecular forms (Stoclet et al., 1995; Loughney & Ferguson, 1996) and at least four dierent subtypes have been shown to coexist in the heart muscle Bode et al., 1991; Dubois et al., 1993; Taira et al., 1993; Engels et al., 1994; Kostic et al. 1997) : (1) a Ca 2+ /calmodulin-activated PDE (PDE1) which hydrolyzes cyclic AMP and cyclic GMP; (2) a cyclic GMPstimulated PDE (PDE2) which hydrolyzes cyclic AMP and cyclic GMP; (3) a cyclic GMP-inhibited PDE (PDE3) which hydrolyzes cyclic AMP with high anity (low K m ) and (4) and a cyclic GMP-independent PDE (PDE4) which hydrolyzes selectively cyclic AMP with high anity. All these PDEs can be inhibited by xanthine derivatives, such as 3-isobutyl-1-metylxanthine (IBMX) or caeine, which have been frequently used to evaluate the role of PDEs in the metabolism of cyclic AMP in cardiac preparations (see e.g. Katano & Endoh, 1993) .
The use of selective or non selective PDE inhibitors has provided some information about the functional importance of PDEs in I Ca regulation . IBMX stimulates basal I Ca in rat (MeÂ ry et al., 1991) and guinea-pig ventricular myocytes (Levi et al., 1989; Ono & Trautwein, 1991; Shiriyama & Pappano, 1996) and enhances the stimulatory eect of cyclic AMP in frog ventricular myocytes (Fischmeister & Hartzell, 1990; MeÂ ry et al., 1995) . Erythro-9-[2-Hydroxy-3-nonyl]adenine (EHNA), a selective PDE2 inhibitor (MeÂ ry et al., 1995; Podzuweit et al., 1995) , stimulates basal I Ca in human atrial cells (Rivet-Bastide et al., 1997) , and antagonizes the inhibitory eect of intracellular cyclic GMP or NO-donors on isoprenaline-or cyclic AMP-stimulated I Ca in frog ventricular myocytes (MeÂ ry et al., 1995) . Inhibition of PDE3 with milrinone results in an increase in basal I Ca in human atrial myocytes (Kirstein et al., 1995) . Similarly, application of intracellular cyclic GMP in guinea-pig ventricular (Shiriyama & Pappano, 1996; Ono & Trautwein, 1991) or human atrial myocytes (Rivet-Bastide et al., 1997) or activation of guanylyl cyclase by NO donors in human atrial myocytes (Kirstein et al., 1995) leads to an increase in I Ca mediated by cyclic GMP inhibition of PDE3. Ro20-1724 or rolipram, two selective PDE4 inhibitors, enhance the response of I Ca to cyclic AMP, isoprenaline or forskolin in frog cardiomyocytes (Fischmeister & Hartzell, 1990; MeÂ ry et al., 1995) .
Despite these previous studies, to our knowledge the respective contribution of any given PDE subtype to the regulation of I Ca or to the control of intracellular cyclic AMP concentration has not been examined at once in the same mammalian cardiac preparation. Thus, the aim of the present study was to get some insight into the respective roles of the four dierent PDE subtypes in the regulation of cardiac I Ca and intracellular cyclic AMP levels in freshly isolated rat ventricular myocytes. After verifying the expression of PDE1-4 subtypes in rat heart by RT ± PCR, we have examined how selective inhibition of one PDE subtype or simultaneous inhibition of two PDE subtypes modulate basal or isoprenaline-stimulated I Ca and intracellular cyclic AMP. I Ca was recorded using the whole-cell patch-clamp technique and intracellular cyclic AMP was measured using radioimmunoassay. Selective PDE inhibition was achieved using 8-methoxymethyl-3-isobutyl-1-methylxanthine (MIMX) for PDE1, EHNA for PDE2, cilostamide for PDE3, and Ro20-1724 for PDE4 (for reviews, see Beavo, 1995; Stoclet et al., 1995) .
A preliminary account of this work was presented at the XVIIIth European Section Meeting of the International Society for Heart Research, Versailles, France, July 1997 .
Methods
The investigation conforms with the European Community guiding principles in the care and use of animals (86/609/CEE, CE O J noL358, 18 December, 1986) and the French decree no87/748 of October 19, 1987 (J O ReÂpublique Franc Ë aise, 20 October, 1987 . Authorizations to perform animal experiments according to this decree were obtained from the French MinisteÁ re de l'Agriculture et de la ForeÃ t (n o 04226, April 12, 1991).
Preparation of rat ventricular myocytes
Rat ventricular myocytes were obtained by retrograde perfusion from hearts of male Wistar rats (200 ± 250 g) as described (MeÂ ry et al., 1991) , with slight modi®cations. Brie¯y, the rats were subjected to anaesthesia by intraperitoneal injection of penthotal and hearts were excised rapidly. The ionic composition of the Ca
2+
-free Ringer solution was as follows (in mM): NaCl 117, KCl 57, NaHCO 3 4.4, KH 2 PO 4 1.5, MgCl 2 1.7, D-glucose 11.7, sodium phosphocreatine 10, taurine 20, and HEPES 21, adjusted to pH 7.1 with NaOH at room temperature. For enzymatic dissociation, 1 mg ml 71 collagenase A (Boehringer Mannhein, Mannhein, Germany) and 300 mM EGTA were added to the Ca 2+ -free Ringer solution, so that the free Ca 2+ concentration was adjusted to 20 mM. The hearts were perfused retrogradedly at a constant ow of 6 ml min 71 and at 378C by Ca
-free solution during 5 min followed by 1 h of perfusion at 4 ml min 71 with the same solution containing collagenase. The ventricles were then separated from atria, chopped ®nely and agitated gently to dissociate individual cells. The resulting cell suspension was ®ltered on a gauze and the cells were allowed to settle down. The supernatant was discarded and cells resuspended four more times in Ca
-free solution containing a progressively increasing calcium concentration. The cells were maintained at 378C until use.
Measurement of rat PDE mRNA expression by reverse transcriptase polymerase chain reaction (RT ± PCR)
Total RNA was prepared from rat isolated ventricular myocytes and rat ventricular tissue using the Trizol RNA puri®cation system (Gibco BRL, Cergy-Pontoise, France). All RNAs were checked in 1% formaldehyde agarose gel. cDNA was prepared from mRNA with random hexanucleotide primers (20 pmol mg 71 RNA) using MMLV reverse transcriptase and the conditions recommended by the manufacturer (Clontech, Palo Alto, CA, U.S.A.). Fifty ng of cDNA were ampli®ed in 50 ml PCR reaction mixture (200 mM dNTPs ®nal concentrations) containing 2.5 U of Taq polymerase in the buer supplied by the manufacturer (Bioprobe Sytems, Montreuil, France), and 1 mM primers. Oligonucleotide primers designed against the C-terminal region of each PDE sub-type were as follows:
PDE1C (Genbank accession number L41045): Forward primer 5'-TTTTCTCCTCTGTGTGACCG-3', reverse primer 5'-GTGTTCCGTTGACTTGACCT-3', fragment size 505 bp; PDE2A2 (Genbank accession number U21101): Forward primer 5'-GAAGGACTATCAGCGAATGC-3', reverse primer 5'-GGATGGTGAACTTGTGGGAC-3', fragment size 461 bp; PDE3B1 (Genbank accession number Z22867): Forward primer 5'-CACCCAGGAAGAACAAATGC-3', reverse primer 5'-AAGCCAGCAGCATCATAGGA-3', fragment size 551 bp; PDE4A5 (Genbank accession number L27057): Forward primer 5'-TACAGTGGTGGAAGTGGCAG-3', reverse primer 5'-GAGCAGAGATGATGGCAGAA-3', fragment size 278 bp; PDE4 B2 (Genbank accession number L27058): Forward primer 5'-GTTCTCCTCTCTACGCCAGCA-3', reverse primer 5'-ACTTGGTAGGGTTGCTCAGGTC-3', fragment size 454 bp; PDE4 D3 (Genbank accession number U09457): Forward primer 5'-GCGTCCTCCTCCTTGATAACTATT-3', reverse pri-mer 5'-CTGACTCGCCATCTTCCTCTAA-3', fragment size 447 bp.
The PCR products were separated on 1.7% agarose gel containing 0.01% ethidium bromide and photographed under UV irradiation at 320 nm. To assess relative quantities of cDNA from each sample, a second PCR ampli®cation was conducted with primers directed to the rat housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as previously described (Grimaldi et al., 1998) . All PCR procedures were performed as follows: 40 cycles and 35 cycles for isolated myocytes and ventricular tissue respectively (45 s at 948C, 50 s at 508C and 1 min at 728C) and a ®nal elongation (7 min at 728C).
Cyclic AMP radioimmunoassay
Freshly isolated ventricular myocytes were prepared as described above from hearts of adult male Wistar rats weighting 200 ± 250 g. Rod-shaped myocytes were counted using a Mallassez cell and resuspended in an adequate volume of the Ca 2+ -free Ringer solution supplemented with 1 mM Ca
2+
, in order to obtain a density of 10 5 cell ml 71 . Each incubation tube contained 500 ml of this cell suspension to which was added successively 5 ml of a 2006 stock solution of the appropriate drug and 500 ml of Ringer solution. Each condition including control (i.e. in absence of any drug) was tested in triplicate. Incubation was carried out at room temperature (20 ± 248C) and lasted 15 min, allowing the cells to settle down. After this period, the supernatant was discarded and replaced by 500 ml of cold (48C) ethanol to stop the reaction. Ethanol was evaporated (1 h at 378C and low pressure) and the pellet was homogenized in 200 ml of buer for cyclic AMP assay (cyclic AMP radioimmunoassay kit, Immunotech, Marseille, France). After centrifugation at 4500 r.p.m. for 5 min, the supernatants were diluted ten times in the same buer and cyclic AMP was assayed according to the instructions provided by the manufacturer.
Electrophysiological experiments
The whole cell con®guration of the patch-clamp technique was used to record the high-threshold L-type calcium current (I Ca ) on Ca 2+ -tolerant rat ventricular myocytes. The cell was routinely depolarized every 8 s from 750 to 0 mV for 400 ms. The use of a holding potential of 750 mV allowed the elimination of fast sodium currents. Potassium currents were blocked by replacing all K + ions with intracellular and extracellular Cs + . For the determination of current-voltage relationships for I Ca (see Figure 4A ) and I Ca inactivation curve (see Figure 4B ), a double pulse voltage clamp protocol was used (Kirstein et al., 1995) . Brie¯y, every 4 s, the membrane potential of the cell, which was normally maintained at its holding value of 750 mV, experienced the following sequence of events: 750 mV for 10 ms, dierent potentials values ranging from 7100 to +100 mV for 200 ms, 750 mV for 3 ms, and 0 mV for 200 ms (see inset in Figure 4B ). Voltage-clamp protocols were generated by a challenger/09-VM programmable function generator (Kinetic Software, Atlanta, GA, U.S.A.). The cells were voltageclamped using a patch-clamp ampli®er (model RK-400; BioLogic, Claix, France). Currents were analogue-®ltered at 3 KHz and digitally sampled at a frequency of 10 kHz using a 12-bit analogue-to-digital converter (DT2827; Data translation, Marlboro, MA, U.S.A.) connected to a PC compatible (386/33 Systempro; Compaq Computer Corp., Houston, TX, U.S.A.). All experiments were done at room temperature (21 ± 258C).
Solutions and drugs
Control external Cs + Ringer solution contained (in mM): NaCl 107.1, CsCl 20, NaHCO 3 4, NaH 2 PO 4 0.8, MgCl 2 1.8, CaCl 2 1.8, D-glucose 5, sodium pyruvate 5 and HEPES 10, adjusted to pH 7.4 with NaOH. Control or drug-containing solutions were applied to the exterior of the cell by placing the cell at the opening of a 250 mm inner diameter capillary tubing from which the external solution was¯owing at a rate of 10 ml min (MeÂ ry et al., 1991) . Patch electrodes (0.5 ± 1 MO) were ®lled with control internal solution containing (in mM): CsCl 119.8, EGTA 5, MgCl 2 4, sodium phosphocreatine 5, Na 2 ATP 3.1, Na 2 GTP 0.42, CaCl 2 (pCa 8.5) 0.062 and HEPES 10, adjusted to pH 7.3 with CsOH.
Isoprenaline, IBMX, MIMX and EHNA were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Cilostamide was purchased from Calbiochem (Meudon, France), and Ro20-1724 was gently provided by HomanLa-Roche (Switzerland).
Data analysis
The maximal amplitude of I Ca was measured as the dierence between the peak inward current and the end-pulse current (I 200 or I 400 ), which was the current amplitude at the end of the 200 or 400 ms duration pulse (Kirstein et al., 1995) . Currents were not compensated for capacitive and leak currents. Cell membrane capacitance and series resistance were measured by exponential analysis of current responses to 1 mV step changes in membrane potential. Membrane capacitance was 130.2+5.0 pF and series resistance 4.0+0.2 MO (n=137 dierent cells). The on-line analysis was made possible by programming a PC compatible computer in Pascal language to determine for each depolarization, peak, and steady state current value. The results are expressed as mean+s.e.mean. In each experimental condition the eects of the drugs tested on I Ca or cyclic AMP levels are expressed as percent change with respect to the values of these parameters under basal conditions, i.e., in the absence of any hormonal stimulation. The variations in I Ca or cyclic AMP induced by the PDE inhibitors were tested for statistical signi®cance by Student's ttest.
Results

Expression of PDE (1 ± 4) in rat heart
Semi-quantitative RT ± PCR analysis with primers speci®c for rat PDE genes was performed on rat ventricular tissue as well as on isolated rat ventricular myocytes in order to check for the expression of PDE1C, PDE2A, PDE3B and PDE4 (A, B and D) subtypes (Figure 1 ). Earlier studies have provided direct or indirect evidence for the presence of these PDE gene products in rat cardiac tissues (Bode et al., 1991; Taira et al., 1993; Engels et al., 1994; Kostic et al., 1997) . Figure 1 shows that rat ventricles ( Figure 1A ) as well as isolated rat ventricular myocytes ( Figure 1B ) express signi®cant amounts of transcripts for each PDE subtype, suggesting the presence of these enzymes in this tissue. In addition, we found that PDE2 and PDE4 transcripts were more abundant than those coding for PDE1 and PDE3.
Eect of PDE inhibitors on basal I Ca
I Ca was measured in isolated rat ventricular myocytes using the whole-cell patch-clamp technique (Hamill et al., 1981) . The eects of PDE inhibitors were ®rst examined on basal I Ca , i.e. in the absence of a stimulated cyclic AMP production. Basal I Ca amplitude was on average 827.3+36.8 pA at 0 mV membrane potential, and mean I Ca density, which represents the ratio of I Ca amplitude to membrane capacitance, was 6.9+0.3 pA/pF (n=137). Figure 2 shows a typical experiment in which the eect of an extracellular application of Ro20-1724 (0.3 mM), a PDE4 inhibitor, was compared with the eect of 100 mM IBMX, a broad-spectrum PDE inhibitor. As shown, application of Ro20-1724 produced no eect on basal I Ca . Table 1 shows that similar results were obtained with MIMX (1 mM), a PDE1 inhibitor, EHNA (10 mM), a PDE2 inhibitor, and cilostamide (0.1 mM), a PDE3 inhibitor, when the compounds were applied under basal conditions.
The lack of eect of selective inhibitors of PDE1-4 on I Ca may indicate that none of the four PDEs is active under basal conditions. Alternatively, it may indicate that inhibition of a single subtype of PDE does not lead to a sucient increase in cyclic AMP to stimulate basal I Ca . To discriminate between these two hypotheses, we examined the eect of IBMX, a broad-spectrum PDE inhibitor, on basal I Ca . The individual experiment of Figure 2 and the summary data of Table 1 show that application of 100 mM IBMX, a concentration which inhibits all PDE subtypes, produced a 42 fold and reversible stimulation of I Ca . This result indicates that, while inhibition of any single PDE subtype is insucient to enhance basal I Ca , complete inhibition of all PDEs produces a sucient accumulation of cyclic AMP to activate basal I Ca .
We next wanted to examine which PDE subtype had a dominant activity under basal condition. To do this, we tested dierent combinations of selective PDE inhibitors for their eect on basal I Ca . In the experiment shown in Figure 3 , the myocyte was initially exposed to 0.1 mM cilostamide which had no eect on basal I Ca (see also Table 1 ). However, when Ro20-1724 (0.1 mM) was applied to the cell in combination with cilostamide, I Ca increased by &40%. Addition of EHNA Figure 1 Expression analysis of PDE1, PDE2, PDE3 and PDE4 transcripts in rat ventricle. RT ± PCR analysis was performed on mRNA extracted from whole ventricular tissue (A) and isolated ventricular myocytes (B) and in the presence (+RT) or in the absence (7RT) (as a negative control) of the reverse transcriptase. The PCR products were analysed on a 1.7% agarose gel and photographs of the ethidium bromide stained gels are shown. The PCR primers used for this analysis and expected length of the PCR products are described in Methods. Positive controls were performed in a second PCR using rat glyceraldehyde 3-phosphate dehydrogenase primers (GAPDH). Positions of two molecular weight markers are indicated in bp. Note that the PCR procedure was 40 cycles and 35 cycles for isolated myocytes and ventricular tissue respectively. This ®gure is representative of three separate determinations of the PDE mRNA expressions obtained by RT ± PCR. (10 mM) on top of the two other PDE inhibitors induced a further increase in I Ca . All the stimulatory eects were completely reversible upon washout of the drugs. Figure 4 shows the current-voltage ( Figure 4A ) and the inactivation relationships ( Figure 4B ) of I Ca obtained in the experiment of Figure 3 , under control condition, in the presence of cilostamide+Ro20-1724 or cilostamide+Ro20-1724+ EHNA. As shown, the combination of cilostamide and Ro20-1724 and the addition of EHNA increased I Ca essentially by the same amount at every membrane potential ( Figure 4A ) which indicates that the stimulatory eects of the drugs were not dependent on membrane potential. The inactivation curve of I Ca ( Figure 4B ) was also unchanged by the presence of the The result are the means+s.e.mean of the number of experiments indicated in the last column. They are expressed in % variation over basal I Ca amplitude. The asterisks indicate when the eects were statistically signi®cant at the P50.01 level (*). Figure 3 in control (squares), in the presence of 0.1 mM cilostamide and 0.1 mM Ro20-1724 (Cil+Ro, circles), and in the presence of 0.1 mM cilostamide, 0.1 mM Ro20-1724 and 10 mM EHNA (Cil+-Ro+EHNA, triangles). Inactivation curves were obtained using a double-pulse protocol indicated in the inset and described in Methods.
drugs which indicates that neither the voltage-dependent nor the Ca-dependent inactivation process (McDonald et al., 1994) was modi®ed. Each of the selective PDE inhibitors was tested in the presence of another inhibitor. This led to six dierent experimental conditions, and the results of these experiments are summarized in Table 1 . Of all the combinations tested, only Ro20-1724 and cilostamide had a signi®cant stimulatory eect on basal I Ca . The dual inhibition of PDE3 and PDE4 resulted in a &50% increase in basal I Ca , an eect which corresponded to &40% of the stimulatory eect observed in the presence of 100 mM IBMX (Table 1) . At this concentration, IBMX increased maximally I Ca , since its eect was not statistically dierent from the stimulation induced by a saturating concentration (1 mM) of isoprenaline (Table 1) . PDE1 inhibition (with 1 mM MIMX) had no eect on basal I Ca under any condition tested (data not shown). PDE2 inhibition (with 10 mM EHNA) had no eect unless PDE3 and PDE4 were simultaneously blocked (data not shown). As shown in Table 1 , the concomitant inhibition of PDE2, PDE3 and PDE4 with a combination of EHNA, cilostamide and Ro20-1724 led to a similar increase in I Ca as that produced by IBMX or isoprenaline.
Eect of PDE inhibitors on isoprenaline-stimulated I Ca
We next examined the respective contribution of each PDE subtype in the regulation of phosphorylated Ca 2+ channels. To do this, we examined the eects of each selective PDE inhibitor on I Ca which had been stimulated by isoprenaline. However, it was important to use a non-saturating concentration of the badrenoceptor agonist in order to allow I Ca to be further increased by the drugs. A concentration of 1 nM isoprenaline was chosen, which increased I Ca by 38.1+4.1% (n=82, Figure   5 ), i.e. which produced &30% of the maximal stimulatory eect observed with 1 mM isoprenaline or 100 mM IBMX (Table 1) . Figure 5 shows a typical experiment in which the eects of PDE2 and PDE3 inhibition with EHNA and cilostamide, respectively, were successively tested on a rat ventricular myocyte exposed to 1 nM isoprenaline. While, as shown above, 100 nM cilostamide or 10 mM EHNA had no eect on basal I Ca , as low as 30 nM cilostamide or 3 mM EHNA induced a net and reversible stimulation of I Ca on top of that obtained with isoprenaline alone. A similar ®nding was obtained with PDE4 inhibition by Ro20-1724. Indeed, Figure 6 shows that application of 30 nM Ro20-1724 induced a net further increase in I Ca in the presence of 1 nM isoprenaline, while this drug had no eect on basal I Ca when used at a 3 fold higher concentration (Table 1) . Figure 7 summarizes the results of several similar experiments in which various concentrations of EHNA ( Figure  7A ), cilostamide ( Figure 7B ) and Ro20-1724 ( Figure 7C ) were tested for their eect on I Ca pre-stimulated by 1 nM isoprenaline. While all these drugs induced an additional increase in I Ca , the maximal stimulatory eect was the highest with Ro20-1724 (&50% at 30 ± 100 nM), intermediate with cilostamide (&30% at 0.3 ± 1 mM) and the lowest with EHNA (&20% at 1 ± 10 mM). Under the same conditions (with 1 nM isoprenaline), PDE1 inhibition with 3 mM MIMX produced only a weak but signi®cant (P50.05) additional stimulation of I Ca (8.1+1.2%, n=5).
Eect of PDE inhibitors on intracellular cyclic AMP concentration
To get further insights into the mechanism of action of the dierent PDE inhibitors tested on I Ca , we examined their eects on intracellular cyclic AMP concentration ([cAMP] i ) in isolated rat ventricular myocytes. Figure 8 shows the results of cyclic AMP assays performed in ventricular myocytes isolated Figure 8A , ®lled circles), on average the eects of MIMX (1 mM), EHNA (10 mM), cilostamide (0.1 mM) and Ro20-1724 (0.1 mM) on basal [cAMP] i were small (20 ± 30%) and not statistically signi®cant ( Figure 8A ). However, when the inhibitors were used in combination to achieve a concomitant inhibition of two PDE subtypes (tested only on PDE2-4), [cAMP] i increased by 40 ± 50% and the eect became statistically signi®cant (P50.05, Figure 8A ).
[cAMP] i increased further (to &80%) when all three PDE subtypes were inhibited, an eect which was similar to that obtained with a maximal concentration of IBMX (100 mM, Figure 8A ). Figure  8B shows the eects of the selective PDE inhibitors on [cAMP] i when applied in the presence of a sub-maximal concentration of isoprenaline (1 nM). Although the preparation that responded to any single PDE inhibitor also responded by a large increase in [cAMP] i with 1 nM isoprenaline ( Figure 8B , ®lled circles), the average stimulatory eect of 1 nM isoprenaline was small (20%) and not statistically signi®cant ( Figure  8B ). However, in the presence of isoprenaline, any single application of PDE inhibitor (tested only on PDE2-4) induced a large (60 ± 70%) increase in [AMP] i ( Figure 8B ), which was similar to the eect obtained with 1 mM isoprenaline ( Figure  8B ) or 100 mM IBMX ( Figure 8A ).
Discussion
In the recent years, it has become well established that cardiac I Ca as well as myocardial contractility is modulated by cyclic AMP-dependent phosphorylation. An increase in cyclic AMP concentration activates cyclic AMP-dependent protein kinase (PKA), which phosphorylates various proteins, including the L-type Ca 2+ channels, leading to an increase in the mean open probability of individual channels (McDonald et al., 1994; Hartzell et al., 1991; Hove-Madsen et al., 1996) . The cyclic AMP signal, which is generated at the level of the sarcolemmal membrane by adenylyl cyclase, is terminated by cyclic nucleotide phosphodiesterases, a class of enzymes that hydrolyse cyclic AMP into 5'-AMP (Beavo, 1995) . At present, four dierent subtypes of PDE (PDE1-4) have been characterized in mammalian hearts (Taira et al., 1993; Engels et al., 1994; Kostic et al., 1997) . Their intracellular localization and/or respective activities may vary depending on the animal species and/or the cardiac tissue (for reviews, see Beavo, 1995; Stoclet et al., 1995) . In our study, we have con®rmed by RT ± PCR the presence of mRNA transcripts encoding for all four PDE subtypes in isolated rat ventricular myocytes.
Investigation of their functional role has been made possible by the development of pharmacological agents that inhibit selectively their activity. A number of compounds, such as the bypiridine derivatives amrinone and milrinone, have long been used as selective PDE3 inhibitors with therapeutic applications. Among these, cilostamide is by far the most potent inhibitor of PDE3 (Reeves & England, 1990) . The antidepressants Ro-20-1724 or rolipram potentiate the positive inotropic eect of forskolin on the heart by acting as selective inhibitors of PDE4 (Muller et al., 1990) . The adenosine deaminase inhibitor EHNA was recently characterised as a potent PDE2 inhibitor, which is also selective of this PDE subtype as far as other PDEs are concerned (MeÂ ry et al., 1995; Podzuveit et al., 1995) . Potent and selective inhibitors of PDE1 are still to come, although the 8-methoxymethyl-derivative of IBMX, MIMX, has been shown to possess some selectivity at the PDE1 subtype (Wells & Miller, 1988) .
In the present study, we used the broad-spectrum PDE inhibitor IBMX as well as the selective inhibitors MIMX, EHNA, cilostamide and Ro20-1724 to assess the respective roles of PDE1-4 in the regulation of basal and stimulated I Ca and [cAMP] i in rat ventricular myocytes. Some of these PDE inhibitors have been shown earlier to increase I Ca by elevating [cAMP] i . For instance, application of IBMX leads to a large stimulation of basal I Ca in guinea-pig (Mubagwa et al., 1997) , rabbit (Akita et al., 1994; Kajimoto et al., 1997) and human cardiomyocytes (Kajimoto et al., 1997) . Similarly, we found that IBMX also increased basal I Ca in rat ventricular myocytes. This indicates that, in all these preparations: (i) there is a substantial basal activity of adenylyl cyclase which determines a basal cyclic AMP synthesis, and (ii) there is a signi®cant basal PDE activity which limits the degree of cyclic AMPdependent phosphorylation of L-type Ca 2+ -channels. The situation in mammals diers from what was found in frog ventricular myocytes, where IBMX had no eect on I Ca unless the current had been pre-stimulated by isoprenaline, forskolin or cyclic AMP (Fischmeister & Hartzell, 1990; . Thus, in frog cardiomyocytes, unlike in most mammalian species, basal adenylyl cyclase activity is insucient to generate enough cyclic AMP to lead to a stimulation of I Ca even when all PDE activity is blocked.
For this reason, selective PDE inhibitors, such as EHNA or milrinone, have no eect on basal I Ca in frog myocytes (Fischmeister & Hartzell, 1990; MeÂ ry et al., 1995) while they do stimulate basal I Ca in human atrial myocytes (Kirstein et al., 1995; Kajimoto et al., 1997; Rivet-Bastide et al., 1997) . Similarly, PDE3 inhibitors stimulate basal I Ca in rabbit cardiomyocytes (Kajimoto et al., 1997) and exert a positive inotropic eect in guinea-pig left atria (Muller et al., 1990) . However, in this study, we found that none of the selective PDE inhibitors used alone had any signi®cant eect on basal I Ca or [cAMP] i in rat ventricular myocytes. Thus, inhibition of a single PDE subtype is insucient to raise cyclic AMP concentration near Ca 2+ channels to the threshold concentration necessary for I Ca stimulation. The likely explanation for this is that other PDE subtypes accounted for cyclic AMP hydrolysis under such condition. To test this hypothesis, we tried to block two PDE subtypes at the same time using combinations of PDE inhibitors. The only`duo' of inhibitors that was found to enhance basal I Ca was cilostamide and Ro20-1724, indicating that PDE3 and PDE4 were the dominant PDE subtypes regulating basal cyclic AMP concentration and I Ca in rat ventricular myocytes. These results are in agreement with a number of biochemical studies showing a much higher speci®c activity of PDE3 and PDE4 compared with PDE1 and PDE2 in rat heart Bode et al., 1991; Dubois et al., 1993; Picq et al., 1996) . Also, functional experiments have shown that inhibition of PDE3 or PDE4 alone had no eect on the contractile activity of rat heart while a dual PDE3 and PDE4 inhibition produced a strong positive inotropic eect .
Surprisingly, however, we found that not only cilostamide and Ro20-1724 but also any other`duo' combination of PDE2-4 inhibitors induced a substantial elevation in [cAMP] channels in frog ventricular myocytes exposed to isoprenaline . It is also supported by a large body of evidence for distinct intracellular localization of the dierent PDE subtypes. For instance, a substantial amount of PDE3 and PDE4 activity was found in a membrane-bound fraction of rat cardiomyocytes (Weishaar et al., 1987; Kaasic & Ohisalo, 1996; Okruhlicova et al., 1996) which may accentuate the role of these PDE subtypes in the control of sarcolemmal processes, such as cyclic AMP-dependent phosphorylation of L-type Ca 2+ channels. PDE3 and PDE4 have also a 5 ± 30 fold lower K m for cyclic AMP than PDE2 (Bode et al., 1991; Beavo, 1995) , which should attenuate the role of PDE2 in I Ca regulation when [cAMP] i near the membrane is low. This may explain why EHNA did not aect I Ca unless PDE3 and PDE4 were blocked or when their activity was saturated by an enhanced cyclic AMP synthesis in the presence of isoprenaline.
Regulation of I Ca by PDE1 in heart remains unclear. In this study, we found that the PDE1 inhibitor MIMX (Wells & Miller, 1988) had negligible eects on basal I Ca and increased only by 8% isoprenaline stimulated I Ca . However, a major drawback of our experiments is that the solution used in the patch-pipette was adjusted to a free Ca 2+ concentration of pCa 8.5 using 5 mM EGTA. Although the Ca 2+ buering capacity of the pipette solution should only weakly aect the Ca 2+ concentration near the membrane, as evidenced by the presence of a large Ca 2+ -mediated inactivation of I Ca under these conditions, it might abolish a Ca 2+ -calmodulin dependent activation of PDE1 in a remote part of the cell. Nystatin-perforated patch-clamp experiments would be necessary to elucidate the role of PDE1 in the control of I Ca . However, it should be mentioned that biochemical studies have shown that rat heart possesses a much lower PDE1 activity as compared to other PDE subtypes (Dubois et al., 1993 , Bode et al., 1991 .
To the exception of MIMX, all other PDE inhibitors tested exerted a clear stimulation of I Ca after application of 1 nM isoprenaline. This low concentration of the B-adrenoceptor agonist moderately increased the activity of adenylyl cyclase localized in the membrane, bringing the cyclic AMP concentration above threshold for cyclic AMP-dependent phosphorylation of L-type Ca 2+ channels. In these conditions, EHNA, cilostamide or Ro20-1724 were found to further enhance I Ca as well as [cAMP] i . Thus, unlike what was observed under basal conditions, inhibition of any single PDE2-4 subtype stimulates Ca 2+ channel activity when the intracellular cyclic AMP level is above threshold. At their maximal eects, the rank order of potency of the dierent PDE inhibitors on isoprenaline stimulated I Ca was Ro20-17244ci-lostamide4EHNA4MIMX. However, in the case of Ro20-1724, increasing the concentration above the maximal eective concentration (100 nM) produced lower stimulatory eects on I Ca ( Figure 7C ). While, we have no clear explanation for this eect, a similar phenomenon was observed in contractile experiments on guinea-pig heart by Muller et al. (1990) with another PDE4 inhibitor, rolipram. An interesting possibility is that the increase in cyclic AMP and PKA activity that results from PDE4 inhibition leads to phosphorylation and activation of PDE4 as has been shown recently in thyroid cells (Sette & Conti, 1996) .
In summary, our results demonstrate that PDE2, PDE3 and PDE4 regulate I Ca in rat ventricular myocytes. PDE3 and PDE4 are the dominant PDE subtypes involved in the regulation of basal I Ca . Each of these two PDEs possesses a sucient enzymatic activity to fully hydrolyse alone the cyclic AMP produced by the basal activity of adenylyl cyclase. This double hydrolytic system may prevent intracellular cyclic AMP from rising immoderately in the absence of stimulatory hormones or neuromediators. When the cell is challenged by a stimulus activating cyclic AMP production, such as a badrenoceptor agonist, all PDE subtypes become determinant in regulating the intracellular cyclic AMP concentration. Hence, the response of I Ca to a sympathetic stimulation will be determined by the activity of each PDE subtype, with the rank order of potency PDE44PDE34PDE24PDE1.
